INGREZZA® (valbenazine) capsules is the only once-daily treatment for adults with tardive dyskinesia
Help your adult patients with Tardive Dyskinesia (TD)
Not actual size
INGREZZA is the simple, once-daily choice to reduce TD severity1
THE SIMPLE CHOICE
Once-daily INGREZZA is the simple choice to support patient adherence1,2,*EXPLORE DOSING
INGREZZA 80 mg reduced uncontrolled movements in 7 of 10 patients at 6 weeks (post hoc analysis)1,3,†REVIEW EFFICACY
SAVINGS & SUPPORT
$10 or less out-of-pocket is what most patients pay for INGREZZA4SEE SUPPORT OPTIONS
Based on a meta-analysis of 51 studies comparing timing adherence of once-daily vs twice-daily regimens for chronic conditions.
Post hoc analysis included patients who had a baseline and a Week 6 AIMS total score. Reduction in uncontrolled movements as assessed by ≥1-point decrease in AIMS total score.
TREAT FIRST LINE WITH VMAT2 INHIBITORS
VMAT2 inhibitors, like INGREZZA, are recommended as first-line treatment for TD6-8SEE GUIDELINES
ACCESS EXCLUSIVE TARDIVE DYSKINESIA (TD) RESOURCES
Register for access to TD resources, including real-world patient videos and clinical trial videos showing INGREZZA treatment resultsSIGN UP
REFERENCES: 1. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc. 2. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527-539. 3. Data on file. Neurocrine Biosciences, Inc. 4. Data on file as of Q1 2021. Neurocrine Biosciences, Inc. 5. Data on file as of Q3 2021. Neurocrine Biosciences, Inc. 6. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association Publishing, 2020. 7. Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75. 8. Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81(2):19cs12983.